BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25817870)

  • 1. Pharmacological regulation of the cholesterol transport machinery in steroidogenic cells of the testis.
    Aghazadeh Y; Zirkin BR; Papadopoulos V
    Vitam Horm; 2015; 98():189-227. PubMed ID: 25817870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leydig cell aging and hypogonadism.
    Beattie MC; Adekola L; Papadopoulos V; Chen H; Zirkin BR
    Exp Gerontol; 2015 Aug; 68():87-91. PubMed ID: 25700847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
    Borst SE; Yarrow JF
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
    Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone benefits of testosterone replacement therapy in male hypogonadism.
    Tirabassi G; Biagioli A; Balercia G
    Panminerva Med; 2014 Jun; 56(2):151-63. PubMed ID: 24994579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYTHS AND CONTROVERSIES IN HYPOGONADISM TREATMENT OF AGING MALES.
    Ungureanu MC; Costache II; Preda C; Mogoş V; Vulpoi C; Leuştean L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):325-33. PubMed ID: 26204632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
    Magnussen LV
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratoristic strategy in late onset hypogonadism.
    Lombardo F; Lupini C; Meola A; Pallotti F; Gandini L; Lenzi A
    Acta Biomed; 2010; 81 Suppl 1():85-8. PubMed ID: 20518196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining testicular function in aging men.
    Tenover JS
    Int J Impot Res; 2003 Aug; 15 Suppl 4():S3-8. PubMed ID: 12934044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in testosterone therapy for men.
    Corona G; Rastrelli G; Forti G; Maggi M
    J Sex Med; 2011 Mar; 8(3):639-54; quiz 655. PubMed ID: 21711483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-life onset hypogonadism: a review.
    Bassil N; Morley JE
    Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study).
    Shigehara K; Konaka H; Koh E; Nakashima K; Iijima M; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Sugimoto K; Iwamoto T; Mizokami A; Namiki M
    Aging Male; 2017 Sep; 20(3):139-145. PubMed ID: 28347184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices.
    Miner M; Canty DJ; Shabsigh R
    Postgrad Med; 2008 Sep; 120(3):130-53. PubMed ID: 18824832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
    Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
    Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.